Skip to main content

Celldex Therapeutics, Inc.

corporate_fare Company Profile

Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed CLDX - Latest Insights

CLDX
Apr 29, 2026, 8:00 AM EDT
Filing Type: DEF 14A
Importance Score:
7
CLDX
Apr 06, 2026, 10:53 AM EDT
Source: GlobeNewswire
Importance Score:
7
CLDX
Apr 02, 2026, 5:14 PM EDT
Filing Type: 424B5
Importance Score:
8
CLDX
Apr 02, 2026, 8:08 AM EDT
Filing Type: 8-K
Importance Score:
8
CLDX
Apr 01, 2026, 9:48 PM EDT
Source: Reuters
Importance Score:
8
CLDX
Apr 01, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
CLDX
Mar 27, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
CLDX
Mar 01, 2026, 9:45 AM EST
Source: GlobeNewswire
Importance Score:
8
CLDX
Feb 27, 2026, 2:45 PM EST
Source: GlobeNewswire
Importance Score:
9
CLDX
Feb 25, 2026, 4:06 PM EST
Filing Type: 10-K
Importance Score:
8
CLDX
Feb 25, 2026, 4:01 PM EST
Filing Type: 8-K
Importance Score:
8